Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tamanna Haque
Institutions:
Memorial Sloan Kettering Cancer Center,
The Ohio State University Wexner Medical Center
Observed institutions:
Memorial Sloan Kettering Cancer Center,
The Ohio State University Wexner Medical Center
ORCID:
0000-0003-0589-9038
Observed ORCID:
0000-0003-0589-9038
OpenAlex ID:
A5115057753
A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis
2024
·
Tamanna Haque
, Aditi Shastri
, et al.
·
British Journal of Haematology
·
8
PDF
Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia
2026
·
Luca Lanino
, Anthony M. Hunter
, et al.
·
Journal of Clinical Oncology
·
5
Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study
2025
·
Andrew Kuykendall
, Aniket Bankar
, et al.
·
Blood
·
5
PDF
Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial
2025
·
Shivani Handa
, Kristin Koenig
, et al.
·
Cancers
·
1
PDF
Real‐world analysis of CPX ‐351 in AML ‐ MR : A multicentre study from the MARROW consortium
2025
·
Daniel T. Peters
, Deedra Nicolet
, et al.
·
British Journal of Haematology
·
1
PDF
VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy
2026
·
Andrew T. Kuykendall
, Aniket Bankar
, et al.
·
Journal of Clinical Oncology
Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs
2026
·
Jacob D Soumerai
, Meghan C. Thompson
, et al.
·
Blood Advances
Molecular characteristics of therapy-related myeloid neoplasms in PARP inhibitor–treated patients.
2026
·
Tamanna Haque
, Rebecca Denson
, et al.
·
Journal of Clinical Oncology
Abstract CT191: The combination of ruxolitinib and the CDK4/6 inhibitor abemaciclib demonstrates safety and efficacy in previously treated myelofibrosis patients: Results of a Phase I study
2026
·
Jan Bewersdorf
, Andriy Derkach
, et al.
·
Cancer Research
Survival of the Oldest-Old: Allogeneic Transplantation Above 75 Years of Age
2026
·
Richard J. Lin
, Maria Bromberg
, et al.
·
Transplantation and Cellular Therapy
Clonal Hematopoiesis Rates in a Recurrent Venous Thrombosis Population: A Prospective Pilot Study
2026
·
Tamanna Haque
, Arletta Lozanski
, et al.
·
Clinical and Applied Thrombosis/Hemostasis
Show more works
View as search
Works count:
12
Citation count:
20
H-index:
3
I10-index:
Year
Topic
Type
